Is BetterLife Pharma Inc. (BETRF) a Buy, Sell, or Hold?
OTC : BETRF
BetterLife Pharma Inc.
$0.161 USD
$0.0 (-1.8%)
- Volume
- 10.3K
- Average Volume
- 89.83K
- Market Capitalization
- $26.06M
- P/E Ratio
- -17.20
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.17
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.04
Company Overview
OTC
Ahmad Doroudian
Biotechnology
Healthcare
BETRF
7
CA
USD
Liquidity Metrics
-0.11
0.04
0.04
0.00
0.00
Sales & Valuation
-$
0.00
-3.41
-40.93
-0.01
Profitability
-$0.0102
-$1.5M
0.00%
0.00%
19.88%
-780.97%
P/E Metrics
-17.20
0.13
0.13
Analyst Price Target & Rating
2/5
0 Analysts
%
Poll Results
About BetterLife Pharma Inc. (OTC:BETRF) Stock
BetterLife Pharma Inc., a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections. Its diverse product pipeline includes BETR-001, targeting conditions such as major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another candidate, BETR-002, is being developed for benzodiazepine dependency, anxiety, and spasticity. Furthermore, BetterLife Pharma is working on MM-003 for COVID-19 and other respiratory viral infe ... ctions, MM-001 as a localized intravaginal cream for HPV-induced cervical intraepithelial neoplasia, and AP-002 for cancer treatment. The company also maintains a research collaboration with the University of California San Diego, conducting preclinical behavioral pharmacology studies on TD-0148A, a lysergic acid diethylamide derivative solution. Incorporated in 2002, the company operated as Pivot Pharmaceuticals Inc. before officially changing its name to BetterLife Pharma Inc. in December 2019.
2026-07-13 08:00:00
Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor mechanism of action that is already clinically validated and approved by the U.S. Food and Drug Administration (FDA) in multiple marketed migraine therapies.
2026-07-06 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
2026-06-25 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
2026-06-22 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
2026-05-13 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the
Frequently Asked Questions
-
What is the current BetterLife Pharma Inc. (BETRF) stock price?
-
BetterLife Pharma Inc.(OTC:BETRF) stock price is $0.161 in the last trading session. During the trading session, BETRF stock reached the peak price of $0.17 while $0.028 was the lowest point it dropped to. The percentage change in BETRF stock occurred in the recent session was --1.8% while the dollar amount for the price change in BETRF stock was -$0.0.
-
BETRF's industry and sector of operation?
-
The OTC listed BETRF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BETRF?
-
Moira Ong | Chief Financial Officer
Ahmad Doroudian | Founder, CEO & Director
Hooshmand Sheshbaradaran | Chief Operating Officer
Stephen Sangha | Corporate Development Advisor & Director
Douglas L. Drysdale | Executive Chairman & Member of Scientific Advisory Board -
How many employees does BETRF have?
-
Number of BETRF employees currently stands at 7. BETRF operates from 1275 West 6th Avenue, Vancouver, BC V6H 1A6, CA.
-
Link for BETRF official website?
-
Official Website of BETRF is: https://www.abetterlifepharma.com
-
How do I contact BETRF?
-
BETRF could be contacted at phone #778 997 1928 and can also be accessed through its website. BETRF operates from 1275 West 6th Avenue, Vancouver, BC V6H 1A6, CA.
-
How many shares of BETRF are traded daily?
-
The average number of BETRF shares traded daily for last 3 months was 89.83K.
-
What is the market cap of BETRF currently?
-
The market value of BETRF currently stands at $26.06M with its latest stock price at $0.161